Affordable Access

Publisher Website

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis

  • Hatami, Hossein1
  • Sotgiu, Giovanni2
  • Bostanghadiri, Narjess3
  • Abadi, Sahel Shafiee Dolat4
  • Mesgarpour, Bita5
  • Goudarzi, Hossein4
  • Migliori, Giovanni Battista6
  • Nasiri, Mohammad Javad4
  • 1 . Department of Public Health, School of Public Health and Safety; Environmental and Occupational Hazards Control Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • 2 . Unità di Epidemiologia Clinica e Statistica Medica, Dipartimento di Scienze Mediche Chirurgiche e Sperimentali, Università degli Studi di Sassari, Sassari, Italia.
  • 3 . Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • 4 . Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • 5 . Department of Public and International Affairs, National Institute for Medical Research Development - NIMAD - Tehran, Iran.
  • 6 . Istituti Clinici Scientifici Maugeri - IRCCS - Tradate, Italia.
Published Article
Jornal Brasileiro de Pneumologia
Sociedade Brasileira de Pneumologia e Tisiologia
Publication Date
Jan 24, 2022
DOI: 10.36416/1806-3756/e20210384
PMID: 35649043
PMCID: PMC8836629
PubMed Central
  • Systematic Review and Meta-Analysis


Objective: Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening infectious disease. Treatment requires multiple antimicrobial agents used for extended periods of time. The present study sought to evaluate the treatment success rate of bedaquiline-based regimens in MDR-TB patients. Methods: This was a systematic review and meta-analysis of studies published up to March 15, 2021. The pooled treatment success rates and 95% CIs were assessed with the fixed-effect model or the random-effects model. Values of p < 0.05 were considered significant for publication bias. Results: A total of 2,679 articles were retrieved by database searching. Of those, 29 met the inclusion criteria. Of those, 25 were observational studies (including a total of 3,536 patients) and 4 were experimental studies (including a total of 440 patients). The pooled treatment success rate was 74.7% (95% CI, 69.8-79.0) in the observational studies and 86.1% (95% CI, 76.8-92.1; p = 0.00; I2 = 75%) in the experimental studies. There was no evidence of publication bias (p > 0.05). Conclusions: In patients with MDR-TB receiving bedaquiline, culture conversion and treatment success rates are high even in cases of extensive resistance.

Report this publication


Seen <100 times